Retatrutide Shows Significant Weight Loss in Phase 3 TRIUMPH-1 Trial | Retatrutide News

Retatrutide achieved up to 30.3% average weight loss in the Phase 3 TRIUMPH-1 trial. This result highlights its potential in obesity treatment.
Clinical Trials · October 26, 2026